News Archive

The most fundamental way for a nation to build its strength in innovation is to invest in its research universities because this investment brings forth new knowledge and human capital – two key aspects that help accelerate innovation, according to Dr. L Rafael Reif, President of the Massachusetts Institute of Technology (MIT).

“New knowledge is the foundation of all truly important innovation while human capital helps in transforming knowledge into new technologies, solutions, companies and jobs,” explained Dr. Reif, who was delivering a talk titled, ‘Science, Technology and Education: Research Universities as Engines of a Modern Economy’ at Masdar Institute in Abu Dhabi. A large number of staff and faculty members with students and other stakeholders attended the event that was organized as part of the Masdar Institute of Science and Technology’s Distinguished Lecture Series program.

Qiagen has acquired an exclusive worldwide license to a promising biomarker that could aid the diagnosis of a group of blood disorders.

The biomarker calreticulin (CALR) has been found to present mutations in an estimated 15 percent of cases of myeloproliferative neoplasms, a group of blood disorders involving overproduction of blood cells that can cause severe complications.

For nearly a year and a half, there has been word that Cambridge Innovation Center (CIC) — the Massachusetts-based coworking space and business incubator for early-stage startups — would expand and open an office in Baltimore.

As Technical.ly Baltimore reported in July 2013, current plans for CIC Baltimore situates the incubator at 873 W. Baltimore St. near the University of Maryland BioPark. At the time real estate consulting firm Cross Street Partners told Technical.ly Baltimore that the Baltimore-based innovation center — a development project of Wexford company — would be roughly 44,000 square feet when construction is completed in late 2014.

MidAmerica Healthcare Venture Forum, to take place April 22-23 in Chicago, unites active investors with corporate business development executives to facilitate investment opportunities with promising Mid-America based startups.

The event showcases emerging innovation and technology dealflow originating in the Midwest, and has earned the reputation as the premier healthcare investing conference.

The Montgomery County Department of Economic Development is looking for a senior level professional to formulate and implement the County’s economic development strategy related to the growth of the life sciences and health IT industry sectors and to provide policy advice on technology issues in these strategic sectors. The position will foster partnerships and manage projects designed to attract new companies to the County, to enhance the presence of companies in these sectors within the County and to foster a pipeline of new companies in these sectors.

This position will evaluate and make recommendations on the technology policy issues relevant to Montgomery County, and implement creative programs that will expand the County’s technological presence in the global marketplace.   This position affects the County’s economic well-being through the number of additional jobs created, number of companies established, capital raised, and commercial space occupied through new company attraction, retention and growth of existing companies, and a pipeline of startups. The candidate will work collaboratively with DED teammates to build the capabilities and competencies of the Department.

Cultivating Cultures for Ethical STEM (CCE STEM) funds research projects that identify factors that are effacacious in the formation of ethical STEM researchers in all the fields of science and engineering that NSF supports. CCE STEM solicits proposals for research that explores the following: ‘What constitutes ethical STEM research and practice? Which cultural and institutional contexts promote ethical STEM research and practice and why?’ Factors one might consider include: honor codes, professional ethics codes and licensing requirements, an ethic of service and/or service learning, life-long learning requirements, curricula or memberships in organizations (e.g. Engineers without Borders) that stress social responsibility and humanitarian goals, institutions that serve under-represented groups, institutions where academic and research integrity are cultivated at multiple levels, institutions that cultivate ethics across the curriculum, or programs that promote group work, or do not grade. Do certain labs have a ‘culture of academic integrity’? What practices contribute to the establishment and maintenance of ethical cultures and how can these practices be transferred, extended to, and integrated into other research and learning settings?

When Kathleen Sebelius took the helm of one of the largest civilian departments in the federal government, the first thorny issue on her desk was responding to the H1N1 flu virus, a new pandemic flu strain that seemed to target otherwise healthy young people. After less than week on the job her first public speech focused on how the Department of Health and Human Services (HHS), which oversees the Centers for Disease Control and Prevention and Food and Drug Administration, was responding to the public health emergency. She released millions of antiviral drugs from the national stockpile and warned against fake flu cures while calling for continual investment into research to stay ahead of future flu outbreaks. Talks about women’s and children’s health, obesity and AIDS soon followed.

Emergent BioSolutions Inc. today announced successful completion of the last licensure-enabling study in its BioThrax® (Anthrax Vaccine Adsorbed) Post-Exposure Prophylaxis (PEP) program. This clinical study, also known as the non-interference study, was designed to evaluate the pharmacokinetic profile of the antimicrobial ciprofloxacin when administered prior to and following the administration of a three-dose series of BioThrax. It was also designed to evaluate the immune response to BioThrax when administered with or without ciprofloxacin. The primary endpoints were the ratio of the maximum concentration (Cmax) and area under the curve (AUC) for ciprofloxacin and the secondary endpoint was the ratio of the geometric mean titer of the antibody response to BioThrax two weeks following the last dose. The study met the prospectively defined success criteria for both the primary and secondary endpoints. Data from this study show no interaction between ciprofloxacin and BioThrax.

Emergent has submitted the final clinical study report to the Biomedical Advanced Research and Development Authority (BARDA) and the U.S. Food and Drug Administration (FDA). Results from this study will be used to support a supplemental Biologics License Application (sBLA) seeking licensure of a PEP indication for BioThrax to be used in combination with antibiotics in people with suspected or confirmed exposure to anthrax spores. BioThrax is currently licensed for a pre-exposure prophylaxis indication only.

Qiagen NV, the Dutch diagnostics technology company that bought  Gaithersburg-based Digene for $1.6 billion in 2007, is preparing to clear out of Digene’s old offices and move staff to an expanded Germantown headquarters.

The move has  been in the works for years, but Qiagen can finally push forward following recent FDA clearance of its 270,000-square-foot Germantown site for manufacturing the company’s human papillomavirus (HPV) test. That HPV test, developed by Digene, was the impetus for the 2007 acquisition.

The University of Maryland announced today that the 2014 University of Maryland Corporate Connector of the Year Award recipient will be Dr. Michael Pecht and the UMD Center for Advanced Life Cycle Engineering (CALCE).  The UMD Corporate Connect Council annually recognizes a University of Maryland researcher, staff or unit that has achieved significant engagement with the private sector in corporate research, philanthropy, or student support.

Pecht will receive his award as part of the University’s Celebration of Innovation and Partnerships on Tuesday, April 29, 2014 at University House in College Park, Maryland. Pecht’s engagement with the private sector has played a large role in making UMD CALCE, headquartered at the College Park campus, the world’s largest manufacturing consortium in electronic parts reliability engineering, accelerated testing, and supply chain management. Over 150 corporations, federal labs, universities and leading international research centers are members.